Tenascin-C targeting strategies in cancer - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Matrix Biology Année : 2024

Tenascin-C targeting strategies in cancer

Mots clés

fluorescein isothiocyanate FN fibronectin FNIII fibronectin type III repeat g gram 68Ga gallium-68 GBM glioblastoma HAMA human-anti-mouse antibody HCAb heavy-chain-only antibody HER2 human epidermal growth factor receptor 2 HL Hodgkin's lymphoma HLA human leucocyte antigen HLE-B3 human lens epithelial cells HNSCC head and neck squamous cell carcinoma HSCT hematopoietic stem cell transplantation hTNC human TNC HUVEC human umbilical vein endothelial cells IC50 inhibitory concentration 50 ID injected dose IF immunofluorescence IgG immunoglobulin G IHC immunohistochemistry 131I iodine-131 IL interleukin IU international unit Kd equilibrium dissociation constant kDa kilodalton KPS Karnofsky performance status KRAS Kirsten rat sarcoma viral oncogene LNA locked nucleic acid 177Lu lutetium-177 mAb monoclonal antibody mg milligram ml milliliter ng nanogram MAREMO matrix regulating motif MBS MAREMO binding site MFR magnetic fluorescent radioisotope mRNA messenger RNA Tenascin-C Extracellular matrix Biomarker Diagnostic application Therapeutic approach Tumor Cancer Inflammation Antibody Nanobody Aptamer Peptide Tumor immunity ADA miRNA anti-drug antibodies ADCC microRNA antibody-dependent cell mediated cytotoxicity ADC MMTV-NeuNT antibody-drug-conjugate AgNPs mouse mammary tumor virus-NeuNT metallic silver nanoparticles ApoE MR apolipoprotein E 211At magnetic resonance astatine-211 AML MTD acute myeloid leukemia BALB maximum tolerated dose bagg albino CAF Nb carcinoma associated fibroblasts CAIA nanobody collagen antibody induced arthritis CAR-T NB chimeric antigen receptor-T cell CCR nanobubbles C-chemokine receptor CCL21 NHL chemokine ligand 21 CD non-Hodgkin lymphoma cluster differentiation CDR NK complementarity-determining regions ch natural killer cell chimeric CPTD nM camptothecin prodrug CR nanomolar complete response Cri 4NQO incomplete count recovery 64Cu 4-Nitroquinoline 1-oxide copper-64 CXCL NRP-1 C-X-C motif chemokine ligand DAMP neuropilin-1 danger associated molecular pattern DNA NP deoxyribonucleic acid DOTA nanoparticle dodecane tetraacetic acid DOX NSLC doxorubicin ECM non-small lung carcinomas extracellular matrix EDA NW extra domain A EGFL nanoworm epidermal growth factor-like repeats EGFR OS epidermal growth factor receptor ELISA overall survival enzyme-linked immunosorbent assay EMT OSCC epithelial mesenchymal transition 18F oral squamous cell carcinoma fluorodeoxyglucose Fab PAGRIT fragment antigen-binding FAM pretargeted antibody-guided radioimmunotherapy fluorescein FBG PC-3 fibrinogen like globular domain Fc prostate carcinoma cells fragment cristallin FITC PDAC fluorescein isothiocyanate FN pancreatic ductal adenocarcinoma fibronectin FNIII PD-1 fibronectin type III repeat g programmed cell death protein -1 gram 68Ga PD-L1 gallium-68 GBM programmed death-ligand 1 glioblastoma HAMA PET human-anti-mouse antibody HCAb positron emission tomography heavy-chain-only antibody HER2 Poly-ICLC human epidermal growth factor receptor 2 HL polyinosinic-polycytidylic acid Hodgkin's lymphoma HLA PR human leucocyte antigen HLE-B3 partial response human lens epithelial cells HNSCC PTX head and neck squamous cell carcinoma HSCT paclitaxel hematopoietic stem cell transplantation hTNC RA human TNC HUVEC rheumatoid arthritis human umbilical vein endothelial cells IC50 stable disease inhibitory concentration 50 ID SELEX injected dose IF systemic evolution of ligands by exponential enrichment immunofluorescence IgG SIP immunoglobulin G IHC small immunoprotein immunohistochemistry 131I siRNA iodine-131 IL short interfering RNA interleukin IU SLE international unit Kd systemic lupus erythematosus equilibrium dissociation constant kDa SSL kilodalton KPS nanoliposome Karnofsky performance status KRAS STAT Kirsten rat sarcoma viral oncogene LNA signal transducer and activator of transcription locked nucleic acid 177Lu TA lutetium-177 mAb tenascin assembly monoclonal antibody mg TGF milligram ml tumor growth factor milliliter ng TIL nanogram MAREMO tumor infiltrating leukocyte matrix regulating motif MBS TLR4 MAREMO binding site MFR toll-like receptor 4 magnetic fluorescent radioisotope mRNA t-Lyp-1 messenger RNA miRNA microRNA MMTV-NeuNT mouse mammary tumor virus-NeuNT MR magnetic resonance MTD maximum tolerated dose Nb nanobody NB nanobubbles NHL non-Hodgkin lymphoma NK natural killer cell nM nanomolar 4NQO 4-Nitroquinoline 1-oxide NRP-1 neuropilin-1 NP nanoparticle NSLC non-small lung carcinomas NW nanoworm OS overall survival OSCC oral squamous cell carcinoma PAGRIT pretargeted antibody-guided radioimmunotherapy PC-3 prostate carcinoma cells PDAC pancreatic ductal adenocarcinoma PD-1 programmed cell death protein -1 PD-L1 programmed death-ligand 1 PET positron emission tomography Poly-ICLC polyinosinic-polycytidylic acid PR partial response PTX paclitaxel RA rheumatoid arthritis stable disease SELEX systemic evolution of ligands by exponential enrichment SIP small immunoprotein siRNA short interfering RNA SLE systemic lupus erythematosus SSL nanoliposome STAT signal transducer and activator of transcription TA tenascin assembly TGF tumor growth factor TIL tumor infiltrating leukocyte TLR4 toll-like receptor 4 t-Lyp-1 anti-drug antibodies ADCC antibody-dependent cell mediated cytotoxicity ADC antibody-drug-conjugate AgNPs metallic silver nanoparticles ApoE apolipoprotein E 211At astatine-211 AML acute myeloid leukemia BALB bagg albino CAF carcinoma associated fibroblasts CAIA collagen antibody induced arthritis CAR-T chimeric antigen receptor-T cell CCR C-chemokine receptor CCL21 chemokine ligand 21 CD cluster differentiation CDR complementarity-determining regions ch chimeric CPTD camptothecin prodrug CR complete response Cri incomplete count recovery 64Cu copper-64 CXCL danger associated molecular pattern DNA deoxyribonucleic acid DOTA dodecane tetraacetic acid DOX doxorubicin ECM extracellular matrix EDA extra domain A EGFL epidermal growth factor-like repeats EGFR epidermal growth factor receptor ELISA enzyme-linked immunosorbent assay EMT epithelial mesenchymal transition 18F fluorodeoxyglucose Fab fragment antigen-binding FAM fluorescein FBG fibrinogen like globular domain Fc fragment cristallin FITC

Domaines

Cancer
Fichier principal
Vignette du fichier
1-s2.0-S0945053X24000520-main.pdf (7.81 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
Licence

Dates et versions

hal-04608013 , version 1 (11-06-2024)

Licence

Identifiants

Citer

Sayda Dhaouadi, Balkiss Bouhaouala-Zahar, Gertraud Orend. Tenascin-C targeting strategies in cancer. Matrix Biology, 2024, 130, pp.1-19. ⟨10.1016/j.matbio.2024.04.002⟩. ⟨hal-04608013⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More